A phase I study combining bendamustine with rituximab, etoposide and carboplatin (TREC) in patients with aggressive relapsed or refractory lymphoma

被引：0
作者：
Budde, L. Elizabeth
Martin, Daniel B.
Philip, Mary
Shustov, Andrei R.
Gooley, Theodore
Chen, Tara L.
Libby, Edward N.
Chen, Eric Y.
Kojouri, Kiarash
Langerak, Alan
Roden, Jennifer E.
Kammerer, Britt E.
Knudsen, Nancy L.
Smith, Stephen Douglas
Press, Oliver W.
Gopal, Ajay K.
机构：
[1] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[2] Seattle Canc Care Alliance, Seattle, WA USA
[3] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
[4] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[5] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[6] Univ Washington, Sch Pharm, Seattle, WA 98195 USA
[7] Grp Hlth Permanente, Bellevue, WA USA
[8] Skagit Valley Hosp, Reg Canc Care Ctr, Mt Vernon, WA USA
[9] St Alphonsus Reg Med Ctr, Boise, ID USA
[10] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8533
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma
    Zinzani, Pier Luigi
    Flinn, Ian W.
    Yuen, Sam L. S.
    Topp, Max S.
    Rusconi, Chiara
    Fleury, Isabelle
    Le Du, Katell
    Arthur, Christopher
    Pro, Barbara
    Gritti, Giuseppe
    Crump, Michael
    Petrich, Adam
    Samineni, Divya
    Sinha, Arijit
    Punnoose, Elizabeth A.
    Szafer-Glusman, Edith
    Spielewoy, Nathalie
    Mobasher, Mehrdad
    Humphrey, Kathryn
    Kornacker, Martin
    Hiddemann, Wolfgang
    BLOOD, 2020, 136 (23) : 2628 - 2637
  • [32] Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
    Vacirca, Jeffrey L.
    Acs, Peter I.
    Tabbara, Imad A.
    Rosen, Peter J.
    Lee, Peter
    Lynam, Eric
    ANNALS OF HEMATOLOGY, 2014, 93 (03) : 403 - 409
  • [33] Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
    Jeffrey L. Vacirca
    Peter. I. Acs
    Imad A. Tabbara
    Peter. J. Rosen
    Peter Lee
    Eric Lynam
    Annals of Hematology, 2014, 93 : 403 - 409
  • [34] A MULTICENTER PHASE II STUDY OF BENDAMUSTINE WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Kim, W. S.
    Ando, K.
    Niitsu, N.
    Ogura, M.
    Takahashi, N.
    Uike, N.
    Eom, H. Seok
    Chae, Y. S.
    Tobinai, K.
    Terauchi, T.
    Tateishi, U.
    Tatsumi, M.
    Suh, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
  • [35] Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Ohmachi, Ken
    Niitsu, Nozomi
    Uchida, Toshiki
    Kim, Seok Jin
    Ando, Kiyoshi
    Takahashi, Naoki
    Takahashi, Naoto
    Uike, Naokuni
    Eom, Hyeon Seok
    Chae, Yee Soo
    Terauchi, Takashi
    Tateishi, Ukihide
    Tatsumi, Mitsuaki
    Kim, Won Seog
    Tobinai, Kensei
    Suh, Cheolwon
    Ogura, Michinori
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) : 2103 - +
  • [36] HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
    Stevens, Wendy B. C.
    Bakunina, Katerina
    Cuijpers, Marloes
    Chamuleau, Martine
    Beeker, Aart
    Fijnheer, Rob
    Hebart, Holger
    Visser, Hein P. J.
    Doorduijn, Jeanette K.
    Linton, Kim
    Dreyling, Martin
    de Jong, Daphne
    Kersten, Marie Jose
    HEMASPHERE, 2020, 4 (01):
  • [37] A Phase I Study of Vorinostat (V) in Combination with Rituximab (R), Ifosphamide, Carboplatin, and Etoposide (ICE) for Patients with Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma.
    Budde, Lihua E.
    Zhang, Michelle M.
    Shustov, Andrei R.
    Pagel, John M.
    Warr, Thomas A.
    Chen, Tara L.
    Oliveira, George R.
    Gooley, Ted
    Gopal, Ajay K.
    BLOOD, 2009, 114 (22) : 1423 - 1423
  • [38] A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
    Tuscano, Joseph M.
    Maverakis, Emanual
    Groshen, Susan
    Tsao-Wei, Denice
    Luxardi, Guillaume
    Merleev, Alexander A.
    Beaven, Anne
    DiPersio, John F.
    Popplewell, Leslie
    Chen, Robert
    Kirschbaum, Mark
    Schroeder, Mark A.
    Newman, Edward M.
    CLINICAL CANCER RESEARCH, 2019, 25 (23) : 7004 - 7013
  • [39] A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma
    Bond, David A.
    Huang, Ying
    Christian, Beth A.
    Jaglowski, Samantha
    Benson, Don
    Alinari, Lapo
    Baiocchi, Robert A.
    Cohen, Jonathon B.
    Blum, Kristie A.
    Maddocks, Kami J.
    LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1750 - 1753
  • [40] Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
    Flowers, Christopher R.
    Matasar, Matthew J.
    Herrera, Alex F.
    Hertzberg, Mark
    Assouline, Sarit
    Demeter, Judit
    Mcmillan, Andrew
    Mehta, Amitkumar
    Opat, Stephen
    Trneny, Marek
    Musick, Lisa
    Hirata, Jamie
    Yang, Annie
    Sehn, Laurie H.
    HAEMATOLOGICA, 2024, 109 (04) : 1194 - 1205
12345